Stephen P. Hack

5.3k total citations · 2 hit papers
42 papers, 3.1k citations indexed

About

Stephen P. Hack is a scholar working on Oncology, Molecular Biology and Hepatology. According to data from OpenAlex, Stephen P. Hack has authored 42 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 11 papers in Molecular Biology and 11 papers in Hepatology. Recurrent topics in Stephen P. Hack's work include Colorectal Cancer Treatments and Studies (12 papers), Hepatocellular Carcinoma Treatment and Prognosis (9 papers) and Pancreatic and Hepatic Oncology Research (9 papers). Stephen P. Hack is often cited by papers focused on Colorectal Cancer Treatments and Studies (12 papers), Hepatocellular Carcinoma Treatment and Prognosis (9 papers) and Pancreatic and Hepatic Oncology Research (9 papers). Stephen P. Hack collaborates with scholars based in United States, United Kingdom and South Korea. Stephen P. Hack's co-authors include MacDonald J. Christie, Brigitte Dréno, L. Thomas, Michele Maio, James Larkin, Grant A. McArthur, Mario Mandalà, Luis de la Cruz‐Merino, Paolo A. Ascierto and Caroline Dutriaux and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Neuron.

In The Last Decade

Stephen P. Hack

40 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma

2014 1.5k citations James Larkin, Paolo A. Ascierto et al. New England Journal of Medicine profile →
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study

2025 26 citations Daneng Li, Yulei Wang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephen P. Hack United States	25	1.7k	1.7k	561	416	369	42	3.1k
Yibing Yan United States	29	1.9k 1.1×	2.2k 1.3×	462 0.8×	148 0.4×	135 0.4×	85	3.9k
Oliver M. Fischer Germany	16	1.1k 0.6×	1.4k 0.9×	377 0.7×	360 0.9×	91 0.2×	25	2.8k
Stefan Hart Singapore	23	1.0k 0.6×	1.4k 0.9×	273 0.5×	159 0.4×	116 0.3×	30	2.7k
Gregory M. Springett United States	30	2.0k 1.2×	1.9k 1.1×	836 1.5×	341 0.8×	112 0.3×	86	4.4k
Esther Zwick Germany	11	1.2k 0.7×	2.3k 1.4×	302 0.5×	415 1.0×	59 0.2×	12	3.7k
Eric J. Kort United States	26	606 0.4×	1.3k 0.8×	583 1.0×	208 0.5×	231 0.6×	55	2.4k
Geoffrey T. Gibney United States	32	4.0k 2.3×	2.0k 1.2×	1.3k 2.4×	192 0.5×	115 0.3×	123	5.8k
Tokuzo Arao Japan	38	1.4k 0.8×	2.2k 1.3×	1.1k 1.9×	106 0.3×	264 0.7×	90	3.7k
Norbert Prenzel Germany	9	1.3k 0.8×	2.2k 1.3×	370 0.7×	373 0.9×	54 0.1×	9	3.6k
Mario Mancino Italy	19	1.2k 0.7×	1.6k 1.0×	570 1.0×	166 0.4×	44 0.1×	34	2.8k

Countries citing papers authored by Stephen P. Hack

Since Specialization

Citations

This map shows the geographic impact of Stephen P. Hack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen P. Hack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen P. Hack more than expected).

Fields of papers citing papers by Stephen P. Hack

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen P. Hack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen P. Hack. The network helps show where Stephen P. Hack may publish in the future.

Co-authorship network of co-authors of Stephen P. Hack

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen P. Hack. A scholar is included among the top collaborators of Stephen P. Hack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen P. Hack. Stephen P. Hack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yopp, Adam C., et al.. (2026). Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma. Journal of Hepatology.

Yopp, Adam C., Mingkai Chen, Ann‐Lii Cheng, et al.. (2024). LBA39 Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC). Annals of Oncology. 35. S1230–S1230. 35 indexed citations

El-Khoueiry, Anthony B., Zhenggang Ren, Hong Jae Chon, et al.. (2024). Atezolizumab plus chemotherapy with or without bevacizumab in advanced biliary tract cancer: Results from a randomized proof-of-concept phase II trial (IMbrave151).. Journal of Clinical Oncology. 42(3_suppl). 435–435. 4 indexed citations

Shemesh, Colby S., Phyllis Chan, Mathilde Marchand, et al.. (2023). Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition‐Survival Modeling Framework. Clinical Pharmacology & Therapeutics. 114(3). 644–651. 4 indexed citations

Hack, Stephen P., Wendy Verret, Sohail Mulla, et al.. (2021). IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Therapeutic Advances in Medical Oncology. 13. 4277448576–4277448576. 33 indexed citations

Hack, Stephen P., Jessica Spahn, Minshan Chen, et al.. (2020). IMbrave 050: A Phase III Trial of Atezolizumab Plus Bevacizumab in High-Risk Hepatocellular Carcinoma after Curative Resection or Ablation. Future Oncology. 16(15). 975–989. 151 indexed citations

He, Aiwu Ruth, Kazushi Numata, Kyung Ho Lee, et al.. (2020). 986P Efficacy of atezolizumab (atezo) + bevacizumab (bev) after disease progression with atezo monotherapy in patients with previously untreated, unresectable hepatocellular carcinoma (HCC). Annals of Oncology. 31. S690–S690. 4 indexed citations

Hack, Stephen P., Andrew X. Zhu, & Yulei Wang. (2020). Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Frontiers in Immunology. 11. 598877–598877. 184 indexed citations

Shah, Manish A., Yung‐Jue Bang, Florian Lordick, et al.. (2016). Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma. JAMA Oncology. 3(5). 620–620. 209 indexed citations

10.

Bendell, Johanna C., Howard S. Höchster, Lowell L. Hart, et al.. (2015). A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 33(3_suppl). 663–663. 6 indexed citations

11.

Han, Kelong, Jin Y. Jin, Mathilde Marchand, et al.. (2015). Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 76(5). 917–924. 22 indexed citations

12.

Larkin, James, Paolo A. Ascierto, Brigitte Dréno, et al.. (2014). Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma. New England Journal of Medicine. 371(20). 1867–1876. 1491 indexed citations breakdown →

13.

Cunningham, David, Yung‐Jue Bang, Josep Tabernero, et al.. (2013). MetGastric: A randomized phase III study of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction.. Journal of Clinical Oncology. 31(15_suppl). TPS4155–TPS4155. 26 indexed citations

14.

Bendell, Johanna C., Thomas J. Ervin, David Gallinson, et al.. (2013). Treatment Rationale and Study Design for a Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination With Bevacizumab Plus mFOLFOX-6 in Patients With Previously Untreated Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 12(3). 218–222. 30 indexed citations

15.

Bagley, Elena E., et al.. (2005). GABA Transporter Currents Activated by Protein Kinase A Excite Midbrain Neurons during Opioid Withdrawal. Neuron. 45(3). 433–445. 61 indexed citations

16.

Hack, Stephen P., Elena E. Bagley, Billy Chieng, & MacDonald J. Christie. (2005). Induction of δ-Opioid Receptor Function in the Midbrain after Chronic Morphine Treatment. Journal of Neuroscience. 25(12). 3192–3198. 66 indexed citations

17.

Marinelli, Silvia, Stephen A. Schnell, Stephen P. Hack, et al.. (2004). Serotonergic and Nonserotonergic Dorsal Raphe Neurons Are Pharmacologically and Electrophysiologically Heterogeneous. Journal of Neurophysiology. 92(6). 3532–3537. 58 indexed citations

18.

Hack, Stephen P., Christopher W. Vaughan, & MacDonald J. Christie. (2003). Modulation of GABA release during morphine withdrawal in midbrain neurons in vitro. Neuropharmacology. 45(5). 575–584. 73 indexed citations

19.

Vreugdenhil, Martin, Stephen P. Hack, Andreas Draguhn, & John G. R. Jefferys. (2002). Tetanus toxin induces long-term changes in excitation and inhibition in the rat hippocampal CA1 area. Neuroscience. 114(4). 983–994. 23 indexed citations

20.

Jha, Prabhat, C Hermon, J Peto, et al.. (1993). Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk. The Lancet. 341(8853). 1116–1119. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact